Axogen, Inc. · NASDAQ:AXGN
Axogen — Investor Day (November 2026)
18 slides from Axogen's investor day presentation, Nov 9, 2026
Slide 1: Prostate Nerve Reconstruction Investor Event
Prostate Nerve Reconstruction Investor Event November 9, 2026
Slide 2: Forward-looking Statements
Forward-looking Statements This presentation contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995, which are statements that are not historical facts and relate to future conditions, events, or results. These statements are based on management's cu
Slide 3: Michael Dale, President and Chief Executive Officer
Michael Dale President and Chief Executive Officer 3
Slide 4: Our Mission
Our Mission To restore health and improve quality of life by making restoration of peripheral nerve function an expected standard of care. 4
Slide 5: Our Decision to Move Forward with a Prostate Market Launch
Our Decision to Move Forward with a Prostate Market Launch Clinical Need Market Opportunity Surgical Technique Clinical Impact with Avance ® (acellular nerve allograft-arwx) Is market opportunity Is the need real substantial enough to Can we develop a Do clinical outcomes and meaningful to warrant a
Slide 6: Jens Kemp, Chief Marketing Officer
Jens Kemp Chief Marketing Officer 6
Slide 7: Erectile Dysfunction and Incontinence are Significant Side Effects of Prostatectomy
Erectile Dysfunction and Incontinence are Significant Side Effects of Prostatectomy with Substantial Quality of Life Impact ~14%-90% ~40% Recovery of erectile function can be highly of Robotic-Assisted Radical Prostatectomies 7 variable post robotic prostatectomy1 require complete removal of one or
Slide 8: Patients Expect Prostate Cancer Control Without Sacrificing Quality of Life
Patients Expect Prostate Cancer Control Without Sacrificing Quality of Life 93% Quality of life is as important as cancer control Changes in erectile function 87% affected quality of life Doctors should do everything possible 95% to preserve or restore erectile function Avoid or delay treatment beca
Slide 9: Patient Intent Suggests Access to Nerve Reconstruction Would Influence the Care Pathway
Patient Intent Suggests Access to Nerve Reconstruction Would Influence the Care Pathway 88% Would ask their surgeon about nerve reconstruction 78% of radiation patients surveyed would have been more likely to choose surgery 76% of active surveillance patients surveyed would have chosen surgery 87% 8
Slide 10: Hospitals Indicate Pre-reimbursement Pathway is Possible
Hospitals Indicate Pre-reimbursement Pathway is Possible Rated improvement in erectile 84% function recovery as very or extremely important Of urology administrators rate an 87% erectile-function recovery benefit as important Meaningful improvement in ED 80% recovery can justify pre-coverage adoptio
Slide 11: Total Addressable Market
Total Addressable Market Market Expansion Growth Drivers Active Surgical Therapy Radiation Therapy EBRT Surveillance RARP Focal/Ablative therapies o U.S. prostate cancer diagnoses have been increasing approximately 3% Robotic Assisted Prostatectomy annually, expanding the underlying ~110,000 cases p
Slide 12: Erick DeVinney, Chief Scientific Officer
Erick DeVinney Chief Scientific Officer 12
Slide 13: A Nerve Reconstruction Technique Designed for Robotic Workflow
A Nerve Reconstruction Technique Designed for Robotic Workflow Cavernous Nerve Reconstruction Technique Locate proximal and distal 1 IDENTIFY recipient targets Determine the nerve deficit 2 MEASURE length Thaw, size, and trim graft 3 PREPARE as needed Position and suture both the 4 COAPT distal and
Slide 14: Clinical Experience to Date
Clinical Experience to Date . Clinical Experience Study Patients reconstructed with >220 Avance® 15 Clinical sites 15 Surgeons At 6 months Patients treated with at least 117 six months of follow-up Of patients had better than ~80% expected erectile function 86 31 >95% Of patients had return of conti
Slide 15: Recovery of Erectile Function Was Higher Following Nerve Reconstruction Than Historical Controls
Shu et al., Findings: Recovery of Erectile Function Was Higher Following Nerve Reconstruction Than in Published Historical Controls 38 Patients SHIM Scores ≥15 for Historic Reference Controls and reconstructed 100% Reconstruction Patients with Avance® Patients Achieving Erectile Function (%) 80% Uni
Slide 16: Dr. David I. Lee, MD, Professor of Clinical Urology, UC Irvine
Dr. David I. Lee, MD Professor of Clinical Urology – University of California, Irvine EDUCATION • MD – Loma Linda University School of Medicine (1995) • Intern in General Surgery – Thomas Jefferson University Hospital (1995-1996) • Resident in General Surgery – Thomas Jefferson University Hospital (
Slide 17: Q&A
Q&A Michael Dale Lindsey Hartley President and Chief Financial Officer Chief Executive Officer Jens Kemp Erick DeVinney Chief Marketing Chief Scientific Officer Officer Rick Ditto Dr. David I. Lee, MD VP, Global Health Professor of Clinical Economics, Urology – Reimbursement & Policy University of C
Slide 18: Thank you
Thank you © 2026 Axogen Corporation. All rights reserved. The stylized "a" logo is a registered trademark of Axogen Corporation.